The Heather Cutler Foundation’s Post

Cancer Cell Impact Factor: Unveiling the Intricacies of Cancer Cell Impact Factor: Fitlifejourney:Explore the cutting-edge world of cancer research through the lens of Cancer Cell, a renowned scientific journal with a high impact factor. Delve into innovative studies, global collaborations, and translational research that make Cancer Cell a hub for groundbreaking discoveries in the fight against cancer. Uncover the intricacies of its impact factor and understand why this journal stands out in shaping the landscape of cancer science. Read more for blog post, 👇👇 https://lnkd.in/d4WMur5e

Exciting news from the forefront of medical innovation: Delfi Diagnostics has revealed promising results from a proof-of-concept study at the American Association for Cancer Research's annual meeting, in the early detection of ovarian cancer. Leveraging the technology behind their FirstLook liquid biopsy for lung cancer, they've shown that whole-genome sequencing combined with machine learning can effectively identify cancerous patterns in DNA. This breakthrough could be a game-changer in cancer screening, offering hope for earlier detection and treatment. #MedicalInnovation #CancerResearch #EarlyDetection

🚨 Breakthrough in Early Pancreatic Cancer Detection with AI! 🚨 Researchers from Kyoto University and Arkray Inc. have developed an AI-based method to detect early-stage pancreatic cancer, which is typically difficult to diagnose. By analyzing microRNAs and a conventional tumor marker, the system achieved an 83% detection rate for Stage 1 pancreatic cancer, a significant improvement over traditional methods. The AI model also identified early-stage cases with 50% accuracy, compared to 0% previously. This new approach could dramatically improve survival rates, especially with early intervention. The team plans further validation before seeking government approval for clinical use. Their findings were published in the British Journal of Cancer. Resource: https://lnkd.in/gBknQm6b

Dr. Hatim Sabaawy, a leader at the University of Colorado Cancer Center, has received a $750K grant from the National Cancer Institute (NCI) to advance lung cancer research. This project aims to create innovative models for testing immunotherapies, particularly for non-small cell lung cancer, which makes up 80-85% of all lung cancers. By developing more accurate and personalized testing methods, Dr. Sabaawy’s work has the potential to transform how we approach cancer treatment, bringing us closer to more effective and tailored therapies for patients. This research is a true cross-campus collaboration, involving experts from multiple University of Colorado Anschutz Medical Campus departments and institutes. The first grant is just the beginning, with hopes for additional funding to expand this vital work. Together, we’re pushing the boundaries of what’s possible in cancer research and patient care. https://bit.ly/3TcoKGU #CancerResearch #LungCancer #Medicine #CUAnschutz

Exploring Tumour specific electroporation: Promising in cancer therapy. In the dynamic landscape of cancer research, tumour specific electroporation is emerging as a technology with a potential cancer treatment paradigm. ⚡ Electroporation involves the application of electrical pulses to cells, creating transient pores in the cell membrane. Tumour specific electroporation takes this concept to the next level, precisely targeting cancer cells while sparing healthy tissue. 💡 🔬How does it work? Researchers are harnessing the power of electroporation to deliver therapeutic agents directly into cancer cells, improving treatment effectiveness. This targeted approach minimizes collateral damage to surrounding tissues, a significant challenge in conventional cancer therapies. 💊 Drug Delivery Tumour specific electroporation opens new ways for drug delivery in cancer treatment. The technology enables increased uptake of therapeutic agents by cancer cells, potentially increasing the effectiveness of chemotherapy, immunotherapy and other treatment methods. 🌱 Personal Medicine The precision of tumour specific electroporation aligns seamlessly with the concept of personalized medicine. Tailoring treatments to the genetic and molecular profile of individual tumours holds great promise for more effective and less toxic interventions. 🔄 Beyond conventional boundaries This approach challenges traditional boundaries in cancer therapy and offers hope for patients with resistant or intractable cancers. Tumour specific electroporation could be a game changer in the search for more targeted and effective cancer treatments. 🌟 The future beckons As research in this area progresses, the future of tumour specific electroporation looks promising. Collaboration between researchers, clinicians and industry partners is critical to unlocking the full potential of this innovative technology. 👥 💬🔬 https://lnkd.in/erEDmwu3 #CancerInnovation #CancerResearch #Electroporation #Medicaldevice

A New Frontier in Prostate Cancer Research Introduction: - Promising research introduces "evotypes," unique blueprints of prostate cancer. - Understanding whether a cancer follows a common or a less traveled path allows for tailored treatment strategies. Understanding the Study's Approach: Methodology Unpacked: - Analysis of genetic data from tumors of 159 untreated patients using advanced computational tools. -Tools helped identify distinct patterns and mutations within the cancer cell DNA. Key Discoveries: - Identification of two main evolutionary types or "evotypes": "Canonical" and "Alternative." - Highlights the need for treatments tailored to the genetic landscape of each tumor. Implementing the Findings: A Guide for Patients: - Essential for diagnosed individuals to work with healthcare teams to determine their cancer's evotype. - This classification can predict cancer behavior and response to treatments, guiding towards the most effective options. Future Directions: The Road Ahead: - The study is viewed as the beginning of a deeper exploration into the complexity of prostate cancer. - Aims to refine understanding of evotypes and their impact on disease progression and treatment response. - Holds the promise of developing more targeted therapies, enhancing treatment precision, and improving patient outcomes.

Is there a better way to start a new year than to publish a paper with a group of esteemed colleagues many of whom I'd also call friends? Please find our #OpenAccess practical guidance on how to integrate the results of advanced molecular diagnostics into the management of our #patients with #cancer out in American Cancer Society Journals: CA: A Cancer Journal For Physicians below ⬇ We have tried to make this complex topic as accessible as possible to enable caregivers to provide biomarker driven treatments to their patients. While we strongly believe that molecular profiling should be integral part of diagnostic workup of cancer patients, we acknowledge that both access to diagnostics and access to targeted treatments are the main barriers to overcome to allow more patients to benefit from #PrecisionOncology raffaella casolino Debyani Chakravarty Umberto Malapelle luca mazzarella Nicola Normanno Vivek Subbiah, MD Clare Turnbull Andrew Biankin American Cancer Society Wiley https://lnkd.in/ezdpAhsr

Groundbreaking discovery can be a gamechanger in cancer immunotherapy New technique could make human T cells 100 times more potent at killing cancer cells #cancerimmunotherapy #cancerresearch #groundbreakingcancertreatment #tcelltherapy #immunooncology In a groundbreaking discovery, scientists from UC San Francisco (UCSF) and Northwestern Medicine have unlocked the potential to revolutionise cancer treatment. By borrowing insights from cancer itself, researchers enhanced T cells' efficacy, making them over 100 times more potent at eradicating cancer without toxic effects. This breakthrough, published this week in Nature, defies the limitations of current T cell therapies. Unlike existing immunotherapies, the engineered T cells successfully targeted tumours from various organs in mice, showing unprecedented adaptability. Dr. Jaehyuk Choi, an associate professor at Northwestern, expressed optimism, stating, "We used nature's roadmap to make better T cell therapies." Moonlight Bio, their collaborative venture, aims to bring this transformative approach to clinical testing, offering hope for previously incurable cancers. https://lnkd.in/eWcpYV5p

Cancer remains a topic that unfortunately most people will experience either directly or secondhand. Let's face it, cancer research is crucial and while great advancements have been made, there is still a lot to be done. Catch-up on the latest state of cancer research, current challenges, and opportunities for the future in the blog below. #ResearchSavesLives

This May, we acknowledge National Cancer Research Month! The latest American Association for Cancer Research Progress Report reveals both encouraging advancements and areas demanding further focus. Key Takeaways: 💪Increased lifespan & reduced mortality rates for cancer patients. 🎗️Disparities in cancer outcomes and the need for addressing them. 🔬Importance of multi-modal approaches including stratified trials & 3D in vitro modeling. As we look forward, Optics11 Life remains committed to advancing ex vivo tissue models to improve drug discovery and ultimately, patient outcomes. However, the paradigm shift towards 3D in vitro models holds immense promise for the future of cancer research. #NationalCancerResearchMonth #CancerResearch #Optics11Life #ResearchSavesLives